eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | metabolic syndrome x |
| Comorbidity | C0022658|renal disease |
| Sentences | 11 |
| PubMedID- 20071464 | Recent studies suggest that the metabolic syndrome is associated with renal disease. |
| PubMedID- 24744899 | Further, increasing adiponectin levels by targeting the action of ang ii may be a logical and promising approach for the treatment of cardiovascular and renal diseases associated with metabolic syndrome or diabetes. |
| PubMedID- 21961334 | Aim: to study the role of lipid metabolism impairment in renal disease in patients with metabolic syndrome associated with obesity. |
| PubMedID- 26538831 | Influence of malondialdehyde and matrix metalloproteinase-9 on progression of carotid atherosclerosis in chronic renal disease with cardiometabolic syndrome. |
| PubMedID- 22532116 | This review focuses on the importance of the transcription factors peroxisome proliferator-activated receptor alpha, peroxisome proliferator-activated receptor beta, peroxisome proliferator-activated receptor gamma, liver x receptors, farnesoid x receptor, and the pregnane x receptor/steroid and xenobiotic receptor (pxr) on the physiology and pathophysiology of renal diseases associated with obesity and metabolic syndrome. |
| PubMedID- 22773754 | From our results in poko mice at 4 weeks of age, we define the poko mouse as a good model for the study of the initiation and progression of renal disease associated with metabolic syndrome and glucolipotoxicity. |
| PubMedID- 25991066 | In the present study, the relationship between inadequate serum concentrations of vitamin d and metabolic syndrome in patients with end-stage renal disease undergoing hemodialysis was explored. |
| PubMedID- 20490358 | The obese zucker rat is a model for human metabolic syndrome with associated renal disease [22, 23]. |
| PubMedID- 20702470 | Background: the disorders associated with metabolic syndrome (ms) can lead to renal disease. |
| PubMedID- 22829804 | First, the drugs currently used to successfully retard the progression of cardiovascular and renal disease in patients with the metabolic syndrome all have strong direct antioxidant effects. |
| PubMedID- 24601848 | It has not been elucidated if the concomitant presence of t2dm or metabolic syndrome with end-stage renal disease further impairs the atherogenic profiles. |
Page: 1